I should have been clearer: As far as I know, RCPIQ is not going to merge with or be acquired by anyone. It is $15 million in debt, in fatal bankruptcy (chapter 7), with no actual or prospective source of revenue.
The company mentioned in my previous post, AKER, again, as far as I know, has no relationship with RCPIQ and none is anticipated.
But AKER will merge (somehow) with MyMD Pharmaceuticals which is working with molecules similar to anatabine, a substance which long ago was important to RCPI.
If you have been interested in RCPI for scientific reasons then it's worth looking at MyMD and AKER.
